J&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly after Neumora’s study fail

Johnson & Johnson scrapped its Phase 3 program for aticaprant, an experimental and new type of major depressive disorder drug, following "insufficient efficacy," the pharma giant disclosed late Thursday evening. ...